EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial

Brad C Klein, Rosa Miceli, Lawrence Severt, Peter McAllister, Laszlo Mechtler iD, Jennifer McVige, Merle Diamond, Michael J Marmura, Hua Guo, Michelle Finnegan, Joel M Trugman

Cephalalgia · 2023-01 · 43 (1)

DOI: 10.1177/03331024221128250 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 09.01.2023. Verfasst von Brad C Klein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Abington Neurological Associates, Ltd., Abington, PA, USA. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the long-term safety and tolerability of atogepant in participants who completed the phase 3 ADVANCE trial (NCT03777059).

Methods

This 40-week, open-label extension trial (NCT03939312) monitored safety in participants receiving oral atogepant 60 mg once daily, followed by a four-week safety follow-up period.

Results

Of the 685 participants taking at least one dose of atogepant, the treatment period was completed by 74.6% of participants with a mean (standard deviation) treatment duration of 233.6 (89.3) days. Treatment-emergent adverse events occurred in 62.5% of participants, with upper respiratory tract infection (5.5%), urinary tract infection (5.3%), nasopharyngitis (4.8%), sinusitis (3.6%), constipation (3.4%), and nausea (3.4%) occurring at ≥3%. Serious adverse events were observed in 3.4% of participants (none were treatment-related), and there were no deaths. Adverse events leading to discontinuation occurring at >0.1% were nausea (0.4%) and abdominal pain, vomiting, weight decrease, dizziness, and migraine (0.3% each).

Conclusion

These results are consistent with atogepant’s known safety profile and support long-term use of atogepant 60 mg once daily dosing as safe and well tolerated. ClinicalTrials.gov Registration Number: NCT03939312

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersHumansTreatment OutcomeDouble-Blind MethodNauseaPiperidinesPyridinesPyrrolesSpiro Compounds

Stichwörter der Autor:innen

Atogepantclinical triallong-term safetymigrainepreventivetolerability

Substanzen

atogepantPiperidinesPyridinesPyrrolesSpiro Compounds

Autor:innen und Institutionen

  • Abington Neurological Associates, Ltd., Abington, PA, USA.
  • AbbVie Inc., Madison, NJ, USA.
  • New England Institute for Neurology & Headache, Stamford, CT, USA.
  • DENT Neurologic Institute, Amherst, NY, USA.
  • Diamond Headache Clinic, Chicago, IL, USA.
  • Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.

ORCID-Profile: Laszlo Mechtler

Förderung

  • AbbVie Inc.

Zitieren

APA

Klein, B. C., Miceli, R., Severt, L., McAllister, P., Mechtler, L., McVige, J., Diamond, M., Marmura, M. J., Guo, H., Finnegan, M., & Trugman, J. M. (2023). Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia, 43(1). https://doi.org/10.1177/03331024221128250

Vancouver

Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, et al. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia. 2023;43(1). doi:10.1177/03331024221128250

BibTeX
@article{Klein2023,
  author = {Klein, Brad C and Miceli, Rosa and Severt, Lawrence and McAllister, Peter and Mechtler, Laszlo and McVige, Jennifer and Diamond, Merle and Marmura, Michael J and Guo, Hua and Finnegan, Michelle and Trugman, Joel M},
  title = {Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial},
  journal = {Cephalalgia},
  year = {2023},
  volume = {43},
  number = {1},
  doi = {10.1177/03331024221128250}
}
Kostenlos starten →